ES8704184A1 - Un metodo para producir un polipeptidos similar a lipocortina humana. - Google Patents

Un metodo para producir un polipeptidos similar a lipocortina humana.

Info

Publication number
ES8704184A1
ES8704184A1 ES550784A ES550784A ES8704184A1 ES 8704184 A1 ES8704184 A1 ES 8704184A1 ES 550784 A ES550784 A ES 550784A ES 550784 A ES550784 A ES 550784A ES 8704184 A1 ES8704184 A1 ES 8704184A1
Authority
ES
Spain
Prior art keywords
polypeptides
dna sequences
human lipocortin
processes
recombinant dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES550784A
Other languages
English (en)
Other versions
ES550784A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen NV
Original Assignee
Biogen NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/690,146 external-priority patent/US4879224A/en
Priority claimed from US06/712,376 external-priority patent/US4874743A/en
Application filed by Biogen NV filed Critical Biogen NV
Publication of ES8704184A1 publication Critical patent/ES8704184A1/es
Publication of ES550784A0 publication Critical patent/ES550784A0/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/72—Expression systems using regulatory sequences derived from the lac-operon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

METODO PARA LA PRODUCCION DE UN POLIPEPTIDO SIMILAR A LA LIPOCORTINA HUMANA. CONSISTE EN CULTIVAR UN ORGANISMO HOSPEDANTE TRANSFORMADO POR UNA MOLECULA DE ADN RECOMBINANTE EN UN MEDIO DE CULTIVO Y BAJO CONDICIONES DE CULTIVO APROPIADAS PARA EL HOSPEDANTE, Y EN RECOGER A CONTINUACION EL POLIPEPTIDO DE DICHO MEDIO DE CULTIVO. LA MOLECULA DE ADN RECOMBINANTE COMPRENDE UNA SECUENCIA DE ADN QUE CODIFICA EL POLIPEPTIDO DE UNA MANERA SIMILAR A LA LIPOCORTINA HUMANA, ESTANDO UNIDA OPERATIVAMENTE A UNA SECUENCIA DE CONTROL DE EXPRESION. DE APLICACION COMO AGENTES ANTIINFLAMATORIOS Y TAMBIEN EN EL TRATAMIENTO DE ENFERMEDADES ARTRITICAS, ALERGICAS, DERMATOLOGICASA, OFTALMICAS Y COLAGENICAS.
ES550784A 1985-01-10 1986-01-10 Un metodo para producir un polipeptidos similar a lipocortina humana. Expired ES8704184A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US06/690,146 US4879224A (en) 1985-01-10 1985-01-10 DNA sequences, recombinant DNA molecules and processes for producing human phospholipase inhibitor polypeptides
US06/712,376 US4874743A (en) 1985-01-10 1985-03-15 DNA sequences, recombinant DNA molecules and processes for producing human phospholipase inhibitor-like polypeptides
US76587785A 1985-08-14 1985-08-14
US77289285A 1985-09-05 1985-09-05

Publications (2)

Publication Number Publication Date
ES8704184A1 true ES8704184A1 (es) 1987-03-16
ES550784A0 ES550784A0 (es) 1987-03-16

Family

ID=27505426

Family Applications (1)

Application Number Title Priority Date Filing Date
ES550784A Expired ES8704184A1 (es) 1985-01-10 1986-01-10 Un metodo para producir un polipeptidos similar a lipocortina humana.

Country Status (11)

Country Link
EP (1) EP0209568B1 (es)
JP (4) JPH0787789B2 (es)
CN (1) CN86100721A (es)
AT (1) ATE108830T1 (es)
AU (1) AU601676B2 (es)
DE (1) DE3689977T2 (es)
DK (1) DK433686A (es)
ES (1) ES8704184A1 (es)
FI (1) FI863626A0 (es)
HU (1) HUT40695A (es)
WO (1) WO1986004094A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264550A (en) * 1985-04-15 1993-11-23 Scios Nova Inc. Human anti-inflammatory phospholipase inhibitor protein
AU5770786A (en) * 1985-04-15 1986-11-05 Biotechnology Research Partners Limited Human anti-inflammatory phospholipase inhibitor protein
JPS6256429A (ja) * 1985-09-04 1987-03-12 Teijin Ltd フオスフオリパ−ゼａ↓２阻害活性を有する蛋白
PT87083B (pt) * 1987-03-28 1992-07-31 Boehringer Ingelheim Int Processo para a preparacao de uma proteina anticoagulante vascular, de adn que codifica para esta proteina e de composicoes farmaceuticas que a contem
WO1988007577A1 (en) * 1987-03-31 1988-10-06 Schering Biotech Corporation Glycosylation inhibiting factors
JPH06799B2 (ja) * 1987-04-02 1994-01-05 帝人株式会社 起炎性フオスフオリパ−ゼａ▲下２▼阻害活性を有する蛋白
DE3737237A1 (de) * 1987-11-03 1989-05-18 Behringwerke Ag Anticoagulatorisches protein pp4-x, seine herstellung und verwendung
US5320950A (en) * 1987-11-03 1994-06-14 Behringwerke Aktiengesellschaft DNA encoding anticoagulative protein PP4-X, and its preparation and use
JPH01199995A (ja) * 1988-02-04 1989-08-11 Kyowa Hakko Kogyo Co Ltd ホスホリパーゼａ↓２阻害ペプチド
US5733732A (en) * 1996-01-03 1998-03-31 University Of Iowa Research Foundation Methods for detecting primary adhalinopathy
CA2219299A1 (en) * 1997-10-24 1999-04-24 Elias Georges P-40, a new member of the multidrug resistance gene family
KR100835879B1 (ko) * 2006-10-10 2008-06-09 학교법인 한림대학교 아넥신 융합 단백질
GB2542391A (en) * 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239780A (en) * 1979-10-11 1980-12-16 The Upjohn Company Phospholipase A2 inhibition
US4537858A (en) * 1984-06-22 1985-08-27 E. R. Squibb & Sons, Inc. Plastatin
AU5770786A (en) * 1985-04-15 1986-11-05 Biotechnology Research Partners Limited Human anti-inflammatory phospholipase inhibitor protein

Also Published As

Publication number Publication date
EP0209568B1 (en) 1994-07-20
ATE108830T1 (de) 1994-08-15
JPH0789996A (ja) 1995-04-04
AU601676B2 (en) 1990-09-20
JPH07101994A (ja) 1995-04-18
EP0209568A1 (en) 1987-01-28
AU5318286A (en) 1986-07-29
EP0209568A4 (en) 1988-10-27
JPS62501679A (ja) 1987-07-09
DK433686D0 (da) 1986-09-10
DE3689977D1 (de) 1994-08-25
DK433686A (da) 1986-09-10
JPH0787789B2 (ja) 1995-09-27
JPH0787980A (ja) 1995-04-04
WO1986004094A1 (en) 1986-07-17
ES550784A0 (es) 1987-03-16
CN86100721A (zh) 1987-02-11
FI863626A (fi) 1986-09-09
FI863626A0 (fi) 1986-09-09
DE3689977T2 (de) 1994-10-27
HUT40695A (en) 1987-01-28

Similar Documents

Publication Publication Date Title
ES8704184A1 (es) Un metodo para producir un polipeptidos similar a lipocortina humana.
EP0278776A3 (en) Methods and deoxyribonucleic acid for the preparation of tissue factor protein
ES2094111T3 (es) Proteinas con actividad de factor viii, procedimiento para su produccion que utilizan celulas modificadas por ingenieria genetica y composiciones farmaceuticas que las contienen.
AU5455386A (en) Neovascularization inhibitors and methods for their production and use
AU1049788A (en) Methods and peptides for the treatment of non-ige-mediated diseases
AU1724795A (en) Human tissue inhibitor of metalloproteinase-4
NL189092C (nl) Hybride menselijke leukocytinterferons, dubbelstrengs dna dat hiervoor codeert, expressievector, transformant micro-organisme, werkwijzen ter bereiding daarvan en farmaceutisch preparaat.
IL95480A0 (en) Process for the preparation of cyclic amino acids,and intermediates
GR3017474T3 (en) DNA sequences, recombinant DNA molecules and processes for producing lipocortins III, IV, V & VI.
ES8506347A1 (es) Un metodo para producir un polipeptido de tipo il-2-".
EP0091527A3 (en) Dna sequences, recombinant dna molecules and processes for producing human serum albumin-like polypeptides
HUT65369A (en) Bcrf1 proteins as inhibitors of gamma-interferon
WO2002000822A3 (fr) Nouveau polypeptide, sous-unite humaine 2 $g(b) 16.5 du facteur d'initiation necessaire a la synthese proteique, et polynucleotide codant ce polypeptide
CA2156181A1 (en) Method for obtaining an increased production of a producing celline by using a fusion protocol
WO2001075021A3 (fr) Nouveau polypeptide, proteine humaine associee au transport de glucose 10, et polynucleotide codant pour ce polypeptide
WO2001079428A3 (fr) Nouveau polypeptide, proteine humaine de reparation 8.9 du mesappariement de l'adn, et polynucleotide codant pour ce polypeptide
WO2001079432A3 (fr) Nouveau polypeptide, facteur humain de transcription de la differentiation cellulaire 58, et polynucleotide codant pour ce polypeptide
IT1265649B1 (it) Prodotto dermatologico per uso topico, relativo processo di produzione ed ulizzazione terapeutica nelle ustioni e patologie cutanee.
WO2001083682A3 (fr) Nouveau polypeptide, proteine pax humaine 11.6, et polynucleotide codant pour ce polypeptide
WO2001083685A3 (fr) Nouveau polypeptide, proteine cap 10, et polynucleotide codant pour ce polypeptide
MX9707897A (es) Factor-11 del crecimiento de fibroblastos.
WO2001079436A3 (fr) Nouveau polypeptide, facteur humain de transcription de la differentiation cellulaire 10, et polynucleotide codant pour ce polypeptide
MX9709217A (es) Factor de crecimiento 13 de fibroblastos.
WO2001075033A3 (en) A novel polypeptide, a human cell division cycle regulatory protein 9 and the polynucleotide encoding the polypeptide

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19990201